Skip to main
ENTX

ENTX Stock Forecast & Price Target

ENTX Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Entera Bio is in a strong position to succeed in the clinical development and commercialization of their product candidates, as reflected in the positive feedback from key opinion leaders and the expansion of their collaboration agreement with OPKO Health. Their focus on underserved, chronic medical conditions and potential as a monotherapy treatment makes Entera Bio a promising investment opportunity. However, there are potential risks, including failures in clinical development, competition, and partnership risks, that could impact the achievement of the $10 price target and value of the company.

Bears say

Entera Bio is a clinical-stage biopharmaceutical company that has a negative outlook due to their lack of current product revenue and high losses from changes in fair value of financial liabilities. While the company is developing potential treatments for underserved medical conditions, their limited progress and financial struggles pose a significant risk to their future success. Investors should approach this stock with caution.

ENTX has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Entera Bio Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Entera Bio Ltd (ENTX) Forecast

Analysts have given ENTX a Strong Buy based on their latest research and market trends.

According to 1 analysts, ENTX has a Strong Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Entera Bio Ltd (ENTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.